Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010

BACKGROUND: We examined the change in the use of rosiglitazone-containing products (RCPs) Canada-wide between 2004 and 2010 and whether the rates of adverse events in association with RCP therapy in Canadian patients changed in this period to better understand the real world use of RCP medications a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawson, Nigel SB, Terres, Jorge A Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606324/
https://www.ncbi.nlm.nih.gov/pubmed/23497453
http://dx.doi.org/10.1186/1756-0500-6-82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606324/
https://www.ncbi.nlm.nih.gov/pubmed/23497453
http://dx.doi.org/10.1186/1756-0500-6-82

Ejemplares similares